The Wnt/β-catenin pathway is among the most frequently altered signaling networks in human cancers. Despite decades of preclinical and clinical research, efficient therapeutic targeting of Wnt/β-catenin has been elusive. RNA interference (RNAi) technology silences genes at the mRNA level, and therefore can be applied to previously-undruggable targets. Lipid nanoparticles (LNPs) represent an elegant solution for delivery of RNAi-triggering oligonucleotides to disease-relevant tissues, but have been mostly restricted to applications in the liver. In this study, we systematically tuned the composition of a prototype LNP to enable tumor-selective delivery of a Dicer-substrate siRNA (DsiRNA) targeting CTNNB1, the gene encoding β-catenin. This formulation, termed EnCore-R, demonstrated pharmacodynamic activity in subcutaneous human tumor xenografts, orthotopic patient-derived xenograft (PDx) tumors, disseminated hematopoietic tumors, genetically induced primary liver tumors, metastatic colorectal tumors, murine metastatic melanoma. DsiRNA delivery was homogeneous in tumor sections, selective over normal liver and independent of apolipoprotein-E binding. Significant tumor growth inhibition was achieved in Wnt-dependent colorectal and hepatocellular carcinoma models, but not in Wnt-independent tumors. Finally, no evidence of accelerated blood clearance or sustained liver transaminase elevation was observed after repeated dosing in nonhuman primates. These data support further investigation to gain mechanistic insight, optimize dose regimens and identify efficacious combinations with standard-of-care therapeutics.
Introduction
than 30 base pairs, and contain varying degrees of chemical modification to confer stability and reduce potential for immunostimulatory activation (11) . The mechanism of action for all RNAi triggers that leads to target degradation is well-established. After the therapeutic RNA duplex reaches the cell cytosol, the guide (antisense) strand is bound by the Ago2 endonuclease, which targets its cognate mRNA for cleavage and destruction at a well-defined position exactly ten bases from the 5' end of the guide stand.
Dicer substrate small interfering RNAs (DsiRNAs) are a unique class of RNAi triggers that leverage the microRNA machinery found in all mammalian cells. DsiRNAs are processed by the Dicer enzyme to 21 or 22mer RNA duplexes that are loaded into Ago2 to direct the specific degradation of target mRNAs with high potency and specificity (12) . DsiRNAs have higher intrinsic potency than their cognate conventional siRNAs, which bypass Dicer for many (13, 14) but not all (15) target mRNAs. The often favorable profile of DsiRNAs as a structural class has been hypothesized to involve molecular interactions between the Dicer and Ago2 endonucleases.
To achieve RNA interference in a disease-relevant tissue after systemic administration, the oligonucleotide must have sufficient biodistribution, cell internalization and cytosolic partitioning properties to enable activation of the RNA-induced silencing complex (RISC) and subsequent degradation of the target mRNA. Since RNAi duplexes are inherently unstable, rapidly cleared and cell-impermeable, engineering drug delivery solutions has been a major focus of translational RNAi research for over a decade. Recent efforts have primarily focused on one of two strategies in investigational RNAi therapeutics: ligand-mediated targeting of a liverspecific receptor, or encapsulation in a functionalized nanoparticle that drives biodistribution and cell trafficking (10) . So far, systemic delivery of RNAi triggers has advanced to late clinical 6 development only for targets in the liver, underscoring the difficulty of tumor delivery despite well-validated targets and unmet medical need. A tumor delivery strategy must overcome a unique physiology, which features a malformed vasculature responsible for heterogeneity, hypoxia, acidotic regions and increased interstitial fluid pressure (16) . These features of the microenvironment have been shown to act as challenging barriers to drug delivery (17) (18) (19) . In addition to overcoming complex biology, a clinically viable delivery solution must meet pharmaceutical criteria: stability, scalability, and amenability to good manufacturing practices (GMP). Classes of RNAi delivery formulations that have been investigated as cancer therapeutics either preclinically or clinically include cyclodextrin-based polymers (20) , chitosan particles (21), antibody-linked conjugates (22), carbon nanotubes (23), and lipid nanoparticles (LNPs) (13, (24) (25) (26) .
LNPs and liposomes represent the most clinically advanced class of delivery vehicles for oncology therapeutics (27) . Liposomal doxorubicin, daunorubicin and cytarabine have been approved for indications ranging from metastatic ovarian and breast cancer to acute myelogenous leukemia (AML), and numerous other LNPs and liposomes are in late clinical development. For cytotoxic agents and other small molecules, advances in LNP-based delivery offer the potential for improved pharmacokinetic (PK) properties, tumor bioavailability and therapeutic index. For cell-impermeable oligonucleotides, specialized LNPs enable escape of siRNA payloads from the endosomal compartment of tumor cells to the cytosol, in part by undergoing pH-dependent structural transitions (28). LNP-based formulations for oncology have not yet advanced beyond early clinical evaluation, where the focus has been primarily on tumors with liver involvement (29). Consequently, there is a need for systematic development of LNPs with the ability to deliver RNAi triggers efficiently to tumors of diverse origin, with acceptable tolerability profiles. 7 In this paper, we describe development and characterization of Encore, an LNP system for delivery of DsiRNA to β-catenin-dependent tumors. We describe structure-activity Together, these results demonstrate the feasibility of DsiRNA therapeutics using EnCore LNPs for traditionally undruggable targets. These data advance our knowledge of tumor-centric LNPs as a platform for formulation of RNAi triggers, and support clinical investigation of direct β-catenin inhibitors for cancer.
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Materials and Methods

Materials
Lipid nanoparticle (LNP) formulations
EnCore LNPs were prepared using a two-step mixing process. The first step involved mixing the DsiRNA payload with a cationic liposome to form a solid loaded Core. The cationic liposome was made by extrusion of a mixture of a cationic lipid (e.g., DL-048) and a polyethylene glycol (PEG)-lipid (e.g., DSG-PEG2K). The lipids were mixed in equal volume using either a batch process or an in-line process. The resulting loaded Core was then used in the second mixing step with the envelope lipids to form the final EnCore LNP. A typical mixture of envelope lipids comprised a cationic lipid (e.g., DL-103), DSPC, cholesterol and DSPE-PEG2K. The ethanolic solution of the envelope lipids was mixed with the solution of the loaded Core using either a batch process or an in-line process. The resulting solution was then subjected to diafiltration by KrosFlo Tangential Flow Filtration System (Spectrum Labs, Rancho Dominguez, CA).
Phosphate-buffered saline (PBS) was exchanged into the formulation. The formulation was then 9 concentrated, collected, filtered through 0.22µm membrane and stored at 4°C before vialing. The particle size of the EnCore LNPs was determined by dynamic light scattering (Zetasizer Nano ZS, Malvern, UK) and the mean diameter was in the range of 70-100 nm with a polydispersity of ~0.1-0.2. The concentration of the DsiRNA was measured using UV absorbance chromatography. Lipids quantification test was done by UPLC-CAD assay. Encapsulation efficiency was measured by RiboGreen assay and ranged from 85 to 95%. originally by ATCC and DSMZ using short tandem repeat analysis. Cells were expanded and frozen down at low passage within 1 month after the receipt of the original stocks. Cells were then thawed and used within 5-6 passages for this study. All the cell lines were subjected to mycoplasma testing (IMPACT   TM   1 profile by IDEXX BioResearch, Columbia, MO) before being released for use in studies.
Cell line-derived xenograft models . For tumor growth inhibition studies, animals were randomized and assigned to one of four cohorts and subjected to dosing cycles as described in Results (n=8/cohort, plus 3 additional animals for pharmacokinetic/pharmacodynamics [PK/PD] analysis after the first cycle). B16F10 experimental lung metastases were generated by injecting 7.5x10 5 cells intravenously in nude mice. The disseminated leukemia models were developed by injecting 5x10 6 697, KG-1 and NALM-6 cells intravenously into NOD.CB17-Prkdc scid /NCrHsd (NOD.SCID) mice. CRC liver metastases models were generated by surgically implanting 2x10 6 cells in the spleen of nude mice after midline abdominal incision. After surgery, the abdominal incision was closed with 5-0 to 6-0 absorbable, nonbraided suture and the skin was closed with a single wound clip. Mice were anesthetized with isoflurane before initiating the surgery and during surgery. Buprenorphine was given preoperatively and post-operatively at 0.1 mg/kg subcutaneously for pain relief. All intravenous dosing was performed via lateral tail vein at a total volume of 10 ml/kg. Mice were held in a pathogen-free environment and all procedures involving animals were performed according to protocols approved by Dicerna Pharmaceuticals' Institutional Animal Care and Use Committee (Dicerna-IACUC).
Patient-derived xenograft model
Left liver lobes of 6-8-week-old male Balb/c nude mice were surgically implanted with primary human liver cancer model (LI0050) fragments (2-3 mm in diameter) for tumor development. 
5'RACE-Seq Methods
Total RNA was isolated using the Qiagen RNA miniprep kit (Qiagen) according to the manufacturer's instructions. 5'RACE analysis was performed on 5 µg of total RNA using the GeneRacer kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions with the exception that RNA were directly ligated to the kit 5' Racer Adapter. cDNA generation and RACE amplification were performed using the kit 5' Racer Primer and CTNNB1 specific primer (5'-TGCAGCCCACCAGCTAACGCACTG-3'). A touchdown qPCR protocol was used to improve amplicon specificity. The cDNA library was constructed using the NEBNext mRNA library prep kit (NEB, Ipswich MA) according to the manufacturer's instructions. Briefly, PCR products were purified using AMPure beads and adaptors were ligated followed by pair-end library enrichment by amplification. The cDNA library was purified and validated for size, quality and concentration using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).
The cDNA libraries were multiplexed and sequenced on the Illumina MiSeq platform. Data were filtered and sequences with 15 nucleotides of the 3' end of the RACE adapter were included in downstream analysis. The RACE adapter sequences were trimmed from the reads and the remaining portion was mapped to the CTNNB1 cDNA sequence. Reads that matched to CTNNB1 were reported in the final analysis. 
Results
Structure-activity relationship (SAR) of EnCore LNP components
LNPs have been applied in clinical testing to achieve favorable pharmacological properties for complex biomolecules, including oligonucleotides. We investigated a novel tumor delivery platform for DsiRNA payloads termed EnCore LNPs. This modular system contains a solid pre-manufactured Core to which the oligonucleotide is complexed, and an Envelope layer that contributes to the transfection and biodistribution properties of the particle. We recently reported the activity of a CTNNB1-targeting DsiRNA formulated in a first-generation LNP, hereby termed EnCore-A, in Hep3B orthotopic hepatocellular tumors (13) . The Core and Envelope of EnCore-A each contain a cationic lipid (sometimes referred to as an ionizable lipid because it is expected to be neutral at physiological pH) and a PEGylated lipid ( Figure S1 ). The EnCore manufacturing process is fully scalable, amenable to current good manufacturing process (cGMP) standards, and subjected to analytical release criteria prior to biological evaluation.
These release criteria typically include >90% RNA encapsulation efficiency and a mean diameter ranging from 70-100, depending on formulation components. The EnCore LNP system has been validated for manufacturability, efficacy and safety through formal preclinical IND-enabling studies. DCR-MYC, a first-in-class oncology therapeutic targeting the MYC oncogene, is an EnCore LNP/MYC DsiRNA-based investigational drug currently in clinical testing (30).
To further advance the EnCore LNP technology, we first explored the chemical space around the Core lipid components. Starting from EnCore-A, we generated EnCore-B by replacing DODMA with the novel lipid DL-48 ( Figure 1A ) to study potential differences in bioperformance between a charged dimethylglycine and a neutral piperizine lipid head group. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Next, we generated EnCore-C by extending the acyl chain length of DMPE-PEG of the EnCore-B core from 14 to 18 carbons using DSPE-PEG. The rationale behind this investigation is that longer acyl chains on PEG-lipids can prevent diffusion of the PEG from the particle and therefore affect its PK properties (34). EnCore-A, B and C carrying CTNNB1 DsiRNA ( Figure 1D ). Duration of effect was dependent on the dosing regimen, but robust mRNA KD was observed for at least 5 days after treatment in both single-dose and multiple-dose regimens ( Figure S2 ). Finally, improved duration of KD was observed when the DsiRNA payload was further modified by the incorporation of stabilizing 2'-fluoro nucleotides (36) , suggesting a correlation between RNAi payload stability and tumor PD ( Figure S3 ).
To compare the activity of Encore-A/B/C in tumors relative to normal tissue, we also measured murine Ctnnb1 (mCtnnb1) mRNA levels in the livers of the LS411N tumor bearing mice. Notably, while EnCore-C showed improved mRNA KD activity in tumors relative to its precursor, it resulted in decreased activity in the normal liver compared to the LNPs containing the shorter C14 PEG-lipid ( Figure 1E ). While EnCore-A and -B treatment resulted in a tumor/liver KD ratio of 0.6 to 0.7, indicating higher potency in liver than in tumor, EnCore-C treatment resulted in a tumor/liver KD ratio of 1.3, indicating tumor selectivity. These data contributed to an improved understanding of the structure-activity relationship (SAR) for the Core lipid components.
Next, we sought to investigate the SAR of the Envelope cationic lipid, which previous studies suggested is likely to be the driver of transfection efficiency (37) . EnCore A-C contains DL-036, which contains a dimethylglycine head group and two symmetrical acyl chains ( Figure   2A ). It has been previously suggested that incorporating asymmetric acyl chains into amino lipids can facilitate pH-dependent lipid phase transitions, thereby increasing endosomal release of the payload (38) (39) (40) . In a test set of otherwise identical LNPs, changing the lengths or the number of double bonds of one or both of the acyl chains significantly impacted the CTNNB1 mRNA silencing activity in tumors (Figure 2A ). After three IV doses of 3 mg/kg in LS411N tumor-bearing mice, the KD of the target mRNA varied widely within the test set, from 0-76% (Figure 2A ). Among the LNPs in the test set, the subset containing a short acyl chain length of 12 carbons yielded the highest potency. One of several examples of SAR discovered in this test set was that the activity of the most highly asymmetric lipids was dependent on their degree of unsaturation (see, for example, EnCore-D vs. -E and EnCore-G vs. -H, Figure 2A ). When the asymmetry was reduced by increasing the length of the short acyl chain, the degree of unsaturation was less impactful. These data suggest that transfection activity is highly dependent on the geometry of the EnCore particle surface. We selected the most potent LNP in the test set structures (41), we further modified EnCore-N by changing its negatively charged PEG-lipid, DSPE, with the neutral PEG-lipid DSG, either in the Envelope (EnCore-Q), the Core (EnCore-R), or in both (EnCore-S). Based on the higher potency of EnCore-N, we reasoned that a single IV dose, instead of the three daily doses as used in the preliminary studies, would enable differentiation between the final formulation candidates at non-saturating levels of mRNA knockdown. After a single 5 mg/kg dose in LS411N tumor-bearing mice, there was a trend toward higher potency for LNPs that contain DSPE in the Envelope, but this did not reach statistical significance. (Figure 2B ). Based on these data, EnCore-R was selected as the lead formulation.
To further investigate intratumoral mRNA silencing for the most potent LNPs in this test set, we performed fluorescence in situ hybridization on LS411N tumor sections ( Figure 2C ) 24 hours after administering a single 5 mg/kg dose. Tumor sections were stained for CTNNB1 mRNA (green), as well as mouse Pecam mRNA (also known as CD31, blue), an endothelial marker to outline the host vasculature. The EnCore-C, -N, and -R test articles all showed a marked decrease of CTNNB1 mRNA relative to the untreated control group, with EnCore-R yielding the most robust silencing according to the image intensity quantiation ( Figure 2D ). Importantly, mRNA silencing was generally homogeneous throughout the tumor parenchyma and not concentrated around the blood vessels, suggesting efficient extravasation of the particle.
A single-dose administration in LS411N tumors as well as a second xenograft model, Hep3B hepatocellular carcinoma, suggested that the approximate in vivo tumor ED 50 for EnCore-R/CTNNB1 DsiRNA was between 0.3 and 1 mg/kg in subcutaneous tumors (Fig. 2D) .
Silencing of CTNNB1 in metastatic and disseminated cell line-derived tumor models 
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( Figure S4A &B) . Interestingly, Hep3B tumors are not known to harbor classical mutations in Wnt/β-catenin signaling nodes; however, they are highly sensitive to inhibition of MYC, a wellcharacterized effector and a direct transcriptional target of β-catenin in tumorigenesis (13, 30, 44) . Robust tumor growth inhibition was observed in both models. Efficacy in SW403 tumors also correlated to a near complete depletion of tumor β-catenin protein levels by immunohistochemistry after 2 dosing cycles ( Figure S4C) . Overall, these studies suggest broad applicability for Wnt/β-catenin-dependent tumors regardless of their tissue origin.
As a control for target specificity, we also tested EnCore-R/CTNNB1 in RKO tumors (35). RKO tumors are wild type for APC and CTNNB1, and therefore do not contain activated Wnt signaling, unlike >90% of human colorectal tumors. Importantly, no antitumor efficacy was observed in RKO tumors ( Figure S5 ), suggesting that, as predicted, only Wnt-dependent tumors will respond to β-catenin inhibition.
Apolipoprotein E-independent delivery of DsiRNA to tumors
The B16F10 syngeneic melanoma model ( Figure 3C ) offers the opportunity to investigate LNP-mediated DsiRNA delivery in germline knockout and transgenic animals, as it eliminates the requirement to establish tumors in immunocompromised mice. To explore the mechanism of EnCore-mediated delivery to tumors, we established B16F10 tumors in both wild-type mice and in apolipoprotein E (ApoE)-deficient mice. LNP-mediated delivery to normal hepatocytes has been previously shown to be highly dependent on opsonization of ApoE onto the particle surface, which facilitates endocytosis of the nanoparticle via the low-density lipoprotein receptor (LDLR) (45) . While silencing of the mouse Ctnnb1 gene in the liver was completely abrogated Figure 5B) . Importantly, the RNA interference-based mechanism of action was confirmed by the 5'RACE method (20, 32) followed by nextgeneration sequencing (NGS), which detected significant levels of the predicted Ago2-mediated cleavage product of CTNNB1 mRNA at single-nucleotide resolution ( Figure S7 ).
To investigate the ability of EnCore-R/CTNNB1 DsiRNA to selectively target the PDX tumor over normal adjacent liver, we measured mRNA levels for CTNNB1 and downstream effectors AXIN2 and MYC in the normal adjacent mouse liver as well as in the orthotopic tumor ( Figure 5C ). While mCtnnb1 KD was observed in the normal liver, mAxin2 and mMyc expression were unaffected. These data suggest that the DsiRNA potency was insufficient to have a functional consequence in normal tissue, thereby providing a potential tolerability advantage over LNPs that were developed originally for liver indications (29).
CTNNB1 DsiRNA is efficacious in CTNNB1/KRAS-driven hepatocellular carcinoma (HCC)
Based on the PDX data ( Figure 5 ), we decided to further model the potential of EnCore-R/CTNNB1 DsiRNA for HCC. Plasmids encoding constitutively activated CTNNB1 (S45Y mutation) and KRAS (G12D mutation) were hydrodynamically injected into the livers of wildtype mice, yielding aggressive hepatocellular tumors ( Figure 6 ). In this model, random genomic 
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While the molecular basis for this tumor selectivity is still being elucidated, we have determined that, unlike SNALP-class LNPs (45) , functional delivery to tumors does not require apolipoprotein E optimization. This suggests that the mechanism of cell internalization for EnCore LNPs is different in tumor versus normal liver, and that an exogenous targeting ligand is not necessary to drive homogeneous delivery in the difficult tumor microenvironment (19) .
Continued progress in understanding the basis of delivery, along with our systematic medicinal chemistry approach, will yield LNPs of higher potency and selectivity. Other non-lipid-based RNAi delivery vehicles, including cyclodextrin polymers (54), have also shown promise in preclinical tumor models, although early clinical development appears to have stalled (20) . 
